Reported Sunday, Ivonescimab Monotherapy Reduces Risk Of Death By 27% Versus Pembrolizumab In PD-L1-Positive Advanced NSCLC, Akeso's HARMONi-2 Study Shows

Benzinga Newsdesk www.benzinga.com Positive 95.0%

Neg 0% Neu 0% Pos 95%

Ivonescimab Reduced the Risk of Death by 27% Compared to Pembrolizumab
HARMONi-2 Demonstrated an Improvement in Median Overall Survival of 8.2 Months
PD-L1 High Expression Subgroup: Hazard Ratio = 0.58
Summit is Conducting Global Phase III HARMONi-7 Study in Patients with PD-L1 High-Expressing NSCLC

Comments

No comments yet. Be the first!